ICU Medical (ICUI) Q4 2019 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2019 earnings summary
6 Nov, 2026Executive summary
FY19 revenue fell to $1.266B from $1.400B; lower IV Solutions demand and selected Infusion Consumables weaknesses outweighed HIS integration savings. Profit was below internal expectations.
Service levels reached their best levels in years; adjusted EBITDA was $268M, with nearly $300M in cash after the Pursuit acquisition.
FY19 net income was $101.0M, compared with $28.8M in FY18; operating income was $107.4M versus $29.8M.
Financial highlights
Revenue was $1,266.2M in FY19, down from $1,400.0M in FY18; gross profit was $471.9M versus $570.0M.
Operating expenses were $364.5M, including $80.6M of restructuring, strategic transaction and integration costs; the contingent earn-out fair-value change reduced expenses by $47.4M.
Q4 revenue was $315.5M, gross profit $114.1M, net income $20.6M and diluted EPS $0.96.
Operating cash flow was $101.9M in FY19, down from $160.2M; cash, equivalents and short-term investments ended the year at $292.6M.
Outlook and guidance
FY20 capital expenditures were estimated at $85M–$90M for manufacturing machinery and equipment, customer infusion devices and IT; cash and operating cash flow were expected to fund spending.
Existing cash and expected operating cash flow were considered sufficient for the next 12 months; long-term funding needs include ongoing capital investment and potential acquisitions.
Management expected IV Solutions sales lost from customers without long-term contracts largely would not return; certain weaker non-LVP IV Systems products were expected to remain under pressure.
COVID-19 added uncertainty; operations were described as performing well, with employees increasing production and adapting work practices to maintain customer supply.
Latest events from ICU Medical
- Record revenue and cash flow, led by infusion and oncology, offset critical care pressure.ICUI
Q4 2011 - Record FY09 revenue and earnings accompanied a major shift to direct critical care sales.ICUI
Q4 2009 - Custom and direct-channel growth lifted 2010 results, while Hospira concentration remains a key risk.ICUI
Q4 2010 - Record revenue and stronger margins, offset by lower earnings and critical care sales.ICUI
Q4 2012 - Record FY16 growth funded an infusion transformation, with integration the near-term test.ICUI
Q4 2016 - Record FY15 performance, with growth led by Infusion and Oncology and diversification still critical.ICUI
Q4 2015 - HIS expanded the portfolio, but integration costs drove a FY2017 operating loss.ICUI
Q4 2017 - Integration neared completion as cash grew, but reported earnings absorbed heavy one-time charges.ICUI
Q4 2018 - Infusion Systems growth and record operating cash flow cushioned pandemic-driven weakness elsewhere.ICUI
Q4 2020